ClinicalTrials.gg
CompletedNCT03508700P306Updated Feb 5, 2025Results posted

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD

A Phase 3 interventional study of TNX-102 SL 5.6 mg in PTSD, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-05.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
93
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Enrollment
564th of 1,491
93 · median 65
Started
2018
with 59 others
Phase 3
64 of 1,664
8 open now
Registered
843rd of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 564th largest by enrollment of the 1,491 interventional ones that give a count, is one of 60 that started in 2018, is one of 64 in phase 3, and was the 843rd registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

336 more — sign in →

All 341 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with PTSD who have participated in a double-blind lead-in study and completed an initial 12-week open-label extension study (TNX-CY-P303).

Read the detailed description

This is an open-label, extension trial designed to evaluate safety over 40 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD.

The study will consist of 5 in-clinic study visits, including Baseline Visit 1 (Day 0, which is anticipated to be the same visit as the last visit of the 12-week open-label extension study TNX-CY-P303), followed by in-clinic visits after 7, 16, 28 and 40 weeks of open-label treatment.

03

Conditions studied

  • PTSD

Keywords

  • TNX-102 SL
  • Bedtime
  • Sublingual
  • Safety
  • PTSD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has completed a double-blind lead-in HONOR study and a 12-week open-label extension study P303 and is judged by the investigator as reasonably compliant, with at least 60% compliance with study medication usage (based on drug accountability).
  • The patient has provided written to participate in this extension study.
  • The patient met all prior inclusion and exclusion requirements for the double-blind lead-in HONOR study, or the site received medical monitor approval for the patient to remain in the lead-in study after the retrospective discovery of an entry violation that did not pose any threat to the patient's safety or well-being.
  • During the course of the lead-in HONOR study or 12-week open-label extension P303 study, the patient has had no intervening medical conditions including pregnancy, increase in suicidal ideation (plan or intent) or significant worsening of depression, newly arising clinically significant abnormal laboratory tests, or any clinically significant, uncontrolled, or unstable medical or surgical condition that could affect the patient's ability to participate in the study or potentially compromise the patient's well-being during the study.
  • The patient does not require treatment with a potent (strong) cytochrome P450 subtype 3A4 () inhibitor, or St. John's wort.
  • The patient is willing to refrain from use of all other formulations of cyclobenzaprine for the duration of the study.
  • The patient is willing to refrain from use of monoamine oxidase inhibitors for the duration of the study.
  • Female patients of continue to agree to practice one of the medically acceptable methods of detailed in the lead-in study.

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria for this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    TNX-102 SL 5.6 mg

    2 tablets of TNX-102 SL 2.8 mg taken simultaneously and sublingually (under the tongue) each day at bedtime starting on Day 0 for 40 weeks

    Drug: TNX-102 SL 5.6 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Newly Emergent Adverse Events

    Evaluate the incidence of newly emergent adverse events over an additional 40 weeks of treatment with TNX-102 SL 5.6 mg in patients with PTSD who have participated in a double-blinded lead-in study. Adverse events will be coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized overall and by preferred term and system organ class. Serious AEs and AEs leading to discontinuation of study drug will also be summarized.

    Time frame: 40 weeks

07

Results

Posted Feb 5, 2025

Participant flow

Participant flow — Overall Study
MilestonePlacebo - TNX-102 SLTNX-102 SL - TNX-102 SL
Started4944
Completed2829
Not completed2115

Outcome measures

PrimaryIncidence of Newly Emergent Adverse Events

Evaluate the incidence of newly emergent adverse events over an additional 40 weeks of treatment with TNX-102 SL 5.6 mg in patients with PTSD who have participated in a double-blinded lead-in study. Adverse events will be coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized overall and by preferred term and system organ class. Serious AEs and AEs leading to discontinuation of study drug will also be summarized.

Time frame:
40 weeks
Reported as:
Count of participants · Participants
Incidence of Newly Emergent Adverse Events
ParticipantsPlacebo - TNX-102 SLTNX-102 SL - TNX-102 SL
Incidence of Newly Emergent Adverse Events2619

Adverse events

Collected over 40 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - TNX-102 SL0/49 (0%)0/49 (0%)6/49 (12.2%)
TNX-102 SL - TNX-102 SL0/44 (0%)0/44 (0%)2/44 (4.5%)
Most frequent other events
Most frequent other events
EventPlacebo - TNX-102 SLTNX-102 SL - TNX-102 SL
Hypoaesthesia oralGastrointestinal disorders6/492/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo - TNX-102 SLTNX-102 SL - TNX-102 SLTotal
Mean38.8 ± 9.2934.5 ± 7.9136.8 ± 8.89
Sex: Female, Male
Sex: Female, Male(Participants)Placebo - TNX-102 SLTNX-102 SL - TNX-102 SLTotal
Female8311
Male414182
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo - TNX-102 SLTNX-102 SL - TNX-102 SLTotal
Hispanic or Latino8311
Not Hispanic or Latino414182
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo - TNX-102 SLTNX-102 SL - TNX-102 SLTotal
American Indian or Alaska Native112
Asian347
Native Hawaiian or Other Pacific Islander202
Black or African American9918
White312657
More than one race202
Unknown or Not Reported145
Region of Enrollment
Region of Enrollment(participants)Placebo - TNX-102 SLTNX-102 SL - TNX-102 SLTotal
United States494493
08

Study locations

16 sites
  • Little Rock
    Little Rock, Arkansas 72211, United States
  • Beverly Hills
    Beverly Hills, California 90210, United States
  • Oceanside
    Oceanside, California 92056, United States
  • Orange
    Orange, California 92868, United States
  • Temecula
    Temecula, California 92591, United States
  • Colorado Springs
    Colorado Springs, Colorado 80910, United States
  • Norwich
    Norwich, Connecticut 06360, United States
  • Tampa
    Tampa, Florida 33609, United States
  • Atlanta
    Atlanta, Georgia 30341, United States
  • New Bedford
    New Bedford, Massachusetts 02740, United States
  • Las Vegas
    Las Vegas, Nevada 89102, United States
  • Cedarhurst
    Cedarhurst, New York 11516, United States
  • New York
    New York, New York 10128, United States
  • Canton
    Canton, Ohio 44718, United States
  • Cincinnati
    Cincinnati, Ohio 45219, United States
  • Oklahoma City
    Oklahoma City, Oklahoma 73103, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Sep 2019, 17 months.

Results were first posted in Feb 2025, 5 years 4 months after primary completion. A results delay was requested in Mar 2021.

Of 34 phase 3 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2018
First posted
Apr 26, 2018
StartActual
Apr 19, 2018
Primary completionActual
Sep 30, 2019
CompletionActual
Sep 30, 2019
Results delay requested
Mar 22, 2021
Results first posted
Feb 5, 2025
Last update
Feb 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03508700
Responsible party
Sponsor
First posted
Apr 26, 2018
Start date
Apr 19, 2018
Primary completion
Sep 30, 2019
Completion
Sep 30, 2019
Results posted
Feb 5, 2025
Last update
Feb 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion